Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib‐Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency
Advanced Science · 2025
DOI: 10.1002/advs.202411479 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jiali Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, Jiangsu, 210009,…. Hauptthemen laut MEDLINE: Lung Neoplasms, Glutaminase, Glutamine, Acrylamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province for Excellent Young Scientists, "Double First-Class" university project.
Abstract (Originalsprache)
Overcoming acquired resistance to Osimertinib remains a critical challenge in treating NSCLC. This research indicates that Osimertinib‐resistant cells exhibit a strong dependence on glutamine metabolism. However, targeting GLS1 shows limited anticancer effects, probably because it cannot fully block the glutamine metabolic pathway. The investigation reveals that a more effective strategy involves simultaneously inhibiting both ASCT2 and GLS1. After confirming the efficacy of this dual‐targeting approach against Osimertinib‐resistant cells in preclinical models, the potential of utilizing a broad‐spectrum glutamine metabolism antagonist is further explored to achieve superior antitumor efficacy. DON, broad‐spectrum glutamine antagonist, presents toxicity issues. Herein, the high NQO1 expression in Osimertinib‐resistant NSCLC cells is leveraged to design an NQO1‐responsive DON prodrug, 10e (LBJ‐10e). This prodrug demonstrates superior safety compared to natural DON and greater antitumor activity against resistant tumors compared to the clinical phase II drug DRP104. These findings may address the clinical limitations of GLS1 allosteric inhibitors and underscore prodrug strategies in effectively treating Osimertinib‐resistant lung cancer, providing a foundation for future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
- Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, Jiangsu, 210009, China.
- Center of Drug Screening & Evaluation, Wannan Medical College, Wuhu, Anhui, 241000, China.
ORCID-Profile: Jinlei Bian
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province for Excellent Young Scientists
- "Double First-Class" university project
Zitieren
APA
Huang, J., Zhang, X., Zhang, H., Li, Y., Huang, H., Li, Z., Qiu, Z., Wu, H., Huang, D., Xu, X., & Bian, J. (2025). Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib‐Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency. Advanced Science. https://doi.org/10.1002/advs.202411479
Vancouver
Huang J, Zhang X, Zhang H, Li Y, Huang H, Li Z, et al. Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib‐Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency. Advanced Science. 2025. doi:10.1002/advs.202411479
BibTeX
@article{Huang2025,
author = {Huang, Jiali and Zhang, Xiankang and Zhang, Hui and Li, Yu and Huang, Huidan and Li, Zhiyu and Qiu, Zhixia and Wu, Hongxi and Huang, Dechun and Xu, Xi and Bian, Jinlei},
title = {Addressing Clinical Limitations of Glutaminase Inhibitors: Novel Strategies for Osimertinib‐Resistant Lung Cancer by Exploiting Glutamine Metabolic Dependency},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202411479}
}
EUVIMED